Remarkably, we found that FBXO28 phosphorylation was associated with worse survival also in specific patient subgroups with particularly adverse prognosis, including the most highly proliferative (measured by Ki-67 analysis) and poorly differentiated (high-grade) tumours (Fig 8E) and interestingly, also in Luminal A tumours, which are generally characterized by a uniformly low proliferation status (Supporting Information Fig S7E). Here, FBXO28 is linked to neoplasm.